Hypothesis

Combining timed low-dose melatonin supplementation with evening exposure to narrow-band green light (peak ~530 nm) will restore age‑declined ipRGC-mediated melatonin suppression and significantly increase circadian rhythm amplitude compared with blue‑blocking alone or melatonin monotherapy.

Rationale

Evening blue light suppresses melatonin via ipRGC activation, but ipRGC density and melanopsin signaling decline with age, reducing the efficacy of simple blue‑blocking strategies[1][3]. Green light at ~530 nm preferentially stimulates melanopsin while minimally affecting cone pathways, offering a stronger ipRGC drive without the broad spectral disruption of blue light[5]. Pairing this with a physiological melatonin dose (0.5 mg) taken five hours before habitual sleep onset can reinforce the endogenous signal, counteracting age‑related amplitude loss[6].

Predictions

1. Participants receiving green light + melatonin will show a ≥20 % increase in nocturnal melatonin amplitude (area under the curve) relative to baseline.
2. Actigraphy‑derived interdaily stability will improve by at least 15 % compared with blue‑blocking + placebo.
3. Fasting glucose and triglyceride levels will decrease by ≥10 % after four weeks, reflecting improved peripheral clock synchronization.
4. No significant phase advance will occur, indicating that the intervention enhances amplitude without shifting timing.

Experimental Design

• Population: 120 adults aged 55‑75, stratified by CRY1/PER3 genotype (high vs. low light sensitivity).
• Groups (n=30 each): a. Green light (530 nm, 30 lux, 2 h before bedtime) + 0.5 mg melatonin b. Blue‑blocking glasses (<480 nm filtered) + 0.5 mg melatonin c. Green light + placebo d. Blue‑blocking + placebo
• Duration: 4‑week intervention with a 2‑week washout before crossover.
• Outcomes: Serial salivary melatonin assays (dim‑light melatonin onset, amplitude), wrist actigraphy, fasting metabolic panel, and sleep questionnaires.
• Analysis: Mixed‑effects model testing group × time interaction, with genotype as a covariate.

Potential Outcomes

If the hypothesis holds, green light will rescue ipRGC signaling in older adults, yielding greater circadian amplitude than blue‑blocking alone. A null result would suggest that age‑related ipRGC loss cannot be overcome by spectral shifting alone, directing focus toward pharmacological melanopsin agonists or gene‑based approaches. Either outcome refines the mechanistic understanding of circadian rescue in aging and informs personalized chronotherapy trials.